Abbott seeks U.S. approval for HE4 assay to monitor recurrence/progression of epithelial ovarian cancer

Links shared publicly online about this topic.

1,395
total visits

Abbott seeks U.S. approval for HE4 assay to monitor recurrence/progression of epithelial ovarian cancer

A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the United States. Abbott's ARCHITECT HE4 assay uses a simple blood test to help in monitoring for the recurrence or progression of epithelial ovarian cancer. If approved, this important immunoassay would be the first automated HE4 test available in the United States.

View full resource at news-medical.net

Tags: Cancer, Ovarian Cancer, Lab Test, Women's Health, Physician